US20030095946A1

US20030095946A1 - Il-18 as an osteoclastgenic inhibitor

Info

Publication number: US20030095946A1
Application number: US09/030,061
Authority: US
Inventors: Matthew Todd Gillspie; Nicole Joy Horwood; Nobuyuki Udagawa; Masashi Kurimoto
Original assignee: Hayashibara Seibutsu Kagaku Kenkyujo KK
Current assignee: Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority date: 1997-02-25
Filing date: 1998-02-25
Publication date: 2003-05-22
Also published as: TW570801B; JP3955352B2; EP0861663A2; DE69816502D1; EP0861663A3; US6896880B2; DE69816502T2; KR100520723B1; EP0861663B1; JPH10236974A; KR19980071708A; US20020150555A1

Abstract

An osteoclastgenic inhibitory agent which comprises an interleukin-18 and/or its functional equivalent. The agent can be arbitrarily used as an ingredient for cell culture and agents for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to an osteoclastgenic inhibitory agent comprising an interleukin-18 (hereinafter abbreviated as “IL-18”) or its functional equivalent.

2. Description of the Prior Art

Osteoblasts' bone formation and osteoclasts' bone resorption are well balanced in healthy living bodies, and this keeps the bone tissues in normal conditions while old bone tissues are being replaced with fresh ones without altering the original bone shape. The phenomenon plays an important role in keeping living bodies' homeostasis such as the controlling of blood calcium concentration within a desired range. Once the balance is lost, especially when the bone resorption level exceeds the bone formation level, bone-related diseases and other diseases may be induced. Therefore, elucidation of the whole mechanism of bone resorption in living bodies, particularly, elucidation of osteoclasts is greatly highlighted due to scientific and clinical significance thereof.

However, the mechanism of osteoclast formation has not yet been completely elucidated even though interleukin 1 as a promoter and interleukin 4 as an inhibitor were found. This is because, similarly as various phenomena in living bodies, osteoclast formation in living bodies is controlled by the close and complicated relationship between promoters and inhibitors. Based on these, it is greatly expected to establish an effective osteoclastgenic inhibitory agent from the viewpoint of scientific and clinical aspects.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a novel and effective osteoclastgenic inhibitory agent. To solve the object the present inventors energetically studied for IL-18, i.e., one of cytokines as communication transferring substances in immune systems, which induces production of interferon-γ (hereinafter abbreviated as “IFN-γ”), an important biologically active substance for immunocompetent cells, and granulocyte/macrophage colony-stimulating factor (hereinafter abbreviated as “GM-CSF”), and augments cytotoxicity and induces formation of killer cells. At the finding, IL-18 was described as an interferon-γ-inducing factor as reported by Haruki OKAMURA in Japanese Patent Kokai Nos. 27,189/96 and 193,098/96, and in Nature, Vol. 378, No. 6,552, pp. 88-91 (1995), and then called IL-18 according to the proposal of Shimpei USHIO et al., in The Journal of Immunology, Vol. 156, pp. 4,274-4,279 (1996).

The present inventors found that a particular gene, capable of inhibiting osteoclast formation from osteoclastic precursor cells in vitro, is specifically expressed in quantities in stroma cells derived from mouse myeloma. Their further detailed analysis revealed that (i) the gene encodes IL-18 that includes SEQ ID NO: 7 as a core sequence, (ii) IL-18 and functional equivalents thereof effectively inhibit osteoclast formation, and (iii) the inhibition is mainly due to the action of GM-CSF induced and produced by IL-18.

Based on these, the present inventors solved the present object by an osteoclastgenic inhibitory agent comprising IL-18 or its functional equivalent as an effective ingredient.

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

FIG. 1 shows the structure of the recombinant DNA pKGFHH2. [0009]
FIG. 2 shows the structure of the recombinant DNA pCSHIGIF/MUT35. [0010]
FIG. 3 shows the structure of the recombinant DNA pCSHIGIF/MUT42. [0011]
FIG. 4 shows the structure of the recombinant DNA pBGHuGF. [0012]
FIG. 5 shows the structure of the recombinant DNA pKGFMH2.[0013]
In these figures, KGFHH2 cDNA means a cDNA encoding the IL-18 according to the present invention: IGIF/MUT35; a DNA encoding the IL-18 according to the present invention: IGIF/MUT42; a DNA encoding the IL-18 according to the present invention: HuIGIF; a chromosomal DNA encoding the IL-18 according to the present invention: KGFMH2 cDNA; a CDNA encoding the IL-18 according to the present invention: 5S; a gene for 5S ribosomal RNA: Ptac; a tac promoter: rrnBT1T2; a termination region of a ribosomal RNA operon: AmpR; an ampicillin resistent gene: pBR322ori; a replication origin of [0014] Escherichia coli: CMV; a cytomegalovirus promoter: IFNss; a nucleotide sequence encoding a signal peptide for subtype α2b of human interferon-α.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to an osteoclastgenic inhibitory agent comprising IL-18 or its functional equivalent as an effective ingredient. The wording “IL-18” as referred to in the invention includes polypeptides with the above property independently of their sources and origins. For example, the IL-18 used in the present invention includes, as internal partial amino acid sequences, the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, as well as SEQ ID NO: 4 and SEQ ID NO: 5, and includes the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7 as a whole. The wording “functional equivalent(s)” as referred to in the present invention includes (i) those wherein one or more amino acids in the amino acid sequence of IL-18 are replaced with different amino acids, (ii) those wherein one or more amino acids are added to the N- and/or C-termini of the amino acid sequence of IL-18, (iii) those wherein one or more amino acids are inserted into the internal sites of the amino acid sequence of IL-18, (iv) those wherein one or more amino acids in the N- and/or C-terminal regions of the amino acid sequence of IL-18 are deleted, and (v) those wherein one or more amino acids in the internal regions of the amino acid sequence of IL-18 are deleted; all of these modifications should be made within the range that does not substantially lose the property of osteoclast formation by IL-18 among the inherent property of IL-18. Examples of such functional equivalents are described along with their detailed amino acid sequences in Japanese Patent Application No. 20,906/97 by the same applicant of the present applicant, i.e., polypeptides which are capable of inducing production of interferon-gamma by immunocompetent cells, wherein said polypeptides contain either amino acid sequence wherein one or more cysteines are replaced with different amino acid(s) while leaving respective consensus sequences as shown in SEQ ID NOs: 1, 2 and 4 intact, or that wherein one or more amino acids are added, removed and/or replaced at one or more sites including those in the consensus sequences but excluding those of the replaced cysteine. The different amino acids to replace the cysteine(s) are not restricted to any types, as far as the resulting polypeptide, containing an amino acid sequence replaced with the different amino acid(s), exhibits an activity of inducing production of IFN-γ by immunocompetent cells in the presence or absence of an appropriate cofactor, as the wild-type polypeptides containing SEQ ID NOs: 1, 2 and 4 as consensus partial amino acid sequences, and a stability significantly higher than that of the wild-type polypeptides. The different amino acids include serine, threonine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan, and methionine, among which the most preferable amino acid is serine or alanine. Embodiments of the amino acid sequences, containing SEQ ID NOs: 1, 2 and 4 as consensus partial amino acid sequences, in which one or more cysteines are to be replaced with different amino acid(s) are the wild-type polypeptides containing SEQ ID NO: 6 or 7. SEQ ID NO: 6 contains cysteines at the 38th, 68th, 76th, and 127th positions from the N-terminus. SEQ ID NO: 7 contains cysteines at the 7th, 75th, and 125th positions. The polypeptides include those containing the amino acid sequence of any one of SEQ ID NOs: 20-26, which are derived from the wild-type polypeptide containing SEQ ID NO: 6, those containing the amino acid sequence of SEQ ID NO: 27 or 28, which are derived from the wild-type polypeptide containing the amino acid sequence of SEQ ID NO: 7, and those containing an amino acid sequence derived from any one of SEQ ID NOs: 20-28 by adding, removing, and/or replacing one or more amino acids to and/or at position(s) excepting the positions where the cysteine(s) have been replaced while retaining the desired biological activities and stability. The wording “one or more amino acids” means the number of amino acids which conventional methods such as site-directed mutagenesis can usually add, remove or replace. The polypeptides containing any one of SEQ ID NOs: 20-28 possess both stability and biological activities significantly higher than those of the wild-type polypeptides. [0015]
The functional equivalents as referred to in the present invention further include glycosylated polypeptides of IL-18 and the above polypeptides. Any of these IL-18 and functional equivalents thereof, both of which are included to and referred to as “IL-18” in the present invention, unless specified otherwise, can be used in the present invention independently of their origins; those prepared by separating from natural sources such as cell cultures and from artificially synthesized ones using recombinant DNA technology and peptide synthesis. [0016]
With economical viewpoint, methods of recombinant DNA technology are advantageously used; generally, desired IL-18 can be obtained by introducing DNAs encoding IL-18 into appropriate hosts derived from microorganisms, plants, and animals to form transformants, culturing the transformants in nutrient culture media in a conventional manner, and purifying the cultures by conventional methods used for purifying cytokines. Any DNAs can be used as the above DNAs as long as they contain a DNA encoding IL-18, and can be suitably selected depending on the purpose of the use of the present osteoclastgenic inhibitory agent or on the recombinant DNA technology used. For example, Japanese Patent Kokai Nos. 193,098/96, 231,598/96, and 27,189/96 by the same applicant of the present invention disclose in detail methods for producing IL-18 by culturing transformed microorganisms into which DNAs including a cDNA encoding mouse or human IL-18 are introduced; and Japanese Patent Application No. 185,305/96 by the same applicant of the present invention discloses in detail a method for producing IL-18 encoding human IL-18 by culturing transformed animal cells which have an introduced DNA that includes a chromosomal DNA encodes human IL-18. Japanese Patent Application No. 20,906/97 by the same applicant of the present invention discloses in detail a method for producing IL-18 by culturing transformed animal cells having an introduced DNA which includes a DNA encoding a functional equivalent of human IL-18. [0017]
The aforesaid recombinant DNA technology has an economical advantage, but depending on the hosts and DNA sequences used, the IL-18 thus obtained may have somewhat different physicochemical property from those of IL-18 produced and functions in vivo. Japanese Patent Application No. 67,434/96 by the same applicant of the present invention discloses in detail a preparation of IL-18 using established human cell lines as natural sources, and Japanese Patent Application No. 213,267/96 by the same applicant also discloses in detail the preparation using an interleukin-1β-converting enzyme. The IL-18 obtained by those preparations can be estimated to have substantially the same or equal physicochemical property to that of IL-18 that is produced and functions in vivo, and the yield can be estimated to be slightly lower. However, such IL-18 has an advantage that it has a fewer side effects when used as pharmaceuticals directed to administering to warm-blooded animals in general and including humans. When applying purification methods using monoclonal antibodies specific to IL-18, as disclosed in Japanese Patent Application No. 231,598/96 by the same applicant of the present invention, a relatively-high purity IL-18 can be obtained in a minimum labor and cost. [0018]
The present osteoclastgenic inhibitory agent comprising the aforesaid IL-18 includes any types and forms usable to inhibit osteoclast formation both in vivo and in vitro. The present agent can be advantageously used as ingredients for cell culture media for animal cells, which satisfactorily inhibit osteoclast formation, maintain, proliferate, and/or differentiate the desired cells; components of screening kits for bone-related therapeutic agents; bone-resorption regulatory agents; and agents for osteoclast-related diseases. The bone-resorption regulatory agents include medicaments and health foods that exert an osteoclastgenic inhibitory activity in vivo, control bone resorption to normal conditions, and improve unfavorable physical conditions such as a relatively-insignificant arthralgia. The agents for osteoclast-related diseases include medicaments used to prevent and/or treat diseases caused by an excessive osteoclast formation and/or its function. Examples of such diseases are hypercalcemia, osteoclastoma, Behcet's syndrome, osteosarcoma, arthropathy, chronic rheumatoid arthritis, deformity ostitis, primary hyperthyroidism, osteopenia, and osteoporosis. Varying depending on the types of agents and diseases to be treated, the present agent is usually formulated into a liquid, paste, or solid form which contains 0.000002-100 w/w %, preferably, 0.0002-0.5 w/w % of IL-18. [0019]
The present osteoclastgenic inhibitory agent can be IL-18 alone or compositions comprising IL-18 and one or more other ingredients such as carriers, excipients, diluents, adjuvants, antibiotics, and proteins such as serum albumin and gelatin as stabilizers; saccharides such as glucose, maltose, maltotriose, maltotetraose, trehalose, sucrose, isomaltose, lactose, panose, erlose, palatinose, lactosucrose, raffinose, fructooligosaccharide, galactooligosaccharide, lentinan, dextrin, pullulan, and sugar alcohols including sorbitol, maltitol, lactitol, and maltotriitol; buffers comprising phosphates or citrates mainly; and reductants such as 2-mercaptoethanol, dithiothreitol, and reduced glutathione; and optionally biologically active substances such as interferon-α, interferon-β, interferon-γ, interleukin-2, interleukin-3, interleukin-6, interleukin-12, TNF-α, TNF-β, GM-CSF, estrogen, progesterone, chlormadinone acetate, calcitonin, somatokine, somatomedin, insulin-like growth factor, ipriflavone, parathyroid hormone (PTH), norethisterone, busulfan, ancitabine, cytarabine, fluorouracil, tetrahydrofurfuryl fluorouracil, methotrexate, vitamin D[0020] ₂, active vitamin D, Krestin® or polysaccharide K, L-asparaginase, and OK-432 or Picibanil®; and calcium salts such as calcium lactate, calcium chloride, calcium monohydrogenphosphate, and L-calcium L-aspartate. When used as agents for administering to warm-blooded animals in general and including humans, i.e., agents for osteoclast-related diseases, the present agent can be preferably formulated into compositions by appropriately combining with one or more of the above physiologically-acceptable substances.
The present osteoclastgenic inhibitory agent includes medicaments in a unit dose form used for administering to warm-blooded animals in general and including humans. The wording “unit dose form” means those which contain IL-18 in an amount suitable for a daily dose or in an amount up to four fold by integers or up to {fraction (1/40)} fold of the dose, and those in a physically separated and formulated form suitable for prescribed administrations. Examples of such formulations are injections, liquids, powders, granules, tablets, capsules, troches, collyriums, nebulas, and suppositories. [0021]
The present agent as an osteoclastgenic inhibitory agent effectively treat and prevent osteoclast-related diseases independently of oral and parenteral administrations. Varying depending on the types and symptoms of patients' diseases, the present agent can be administered to the patients orally, intradermally, subcutaneously, muscularly, or intravenously at a dose of about 0.5 μg to 100 mg per shot, preferably, at a dose of about 2 μg to 10 mg per shot of IL-18, 2-6 fold a day or 2-10 fold a week for one day to one year. [0022]
In the below, with reference to experiments, the preparation, physicochemical property, and biological activity of the IL-18 according to the present invention are described: [0023]
Experiment 1 [0024]
Preparation of Human IL-18 [0025]
According to the method in Japanese Patent Kokai No. 231,598/96 by the same applicant of the present invention, an autonomously-replicable recombinant DNA, pKGFHH2, linked to a cDNA encoding human IL-18, was prepared. Dideoxyribonucleotide sequencing analyzed that, as shown in FIG. 1, in the recombinant DNA, KGFHH2 cDNA containing the base sequence of SEQ ID NO: 8 was linked to the downstream of Ptac, a Tac promoter. The recombinant DNA pKGFHH2 contained the amino acid sequences of SEQ ID NOs: 1 to 5; these amino acid sequences were respectively encoded by nucleotides 46-63, 88-105, 400-420, 151-165, and 214-228 in SEQ ID NO: 8. [0026]
According to the method in Japanese Patent Kokai No. 231,598/96, the recombinant DNA pKGFHH2 was introduced into an [0027] Escherichia coli Y1090 strain, ATCC 37197, and the strain was cultured. The produced polypeptide was purified by immunoaffinity chromatography to obtain a purified human IL-18 with a purity of at least 95% in a yield of about 25 mg/l culture. According to the method in Japanese Patent Kokai No. 193,098/96 by the same applicant of the present invention, the purified human IL-18 was analyzed for biological activity and physicochemical property as indicated below: When culturing human lymphocytes, collected by a conventional manner from a healthy donor, in the presence of the purified human IL-18, IFN-γ production was observed depending on the concentration of IL-18, resulting in a confirmation that IL-18 has an activity of inducing IFN-γ production by lymphocytes as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in Nature, Vol. 227, pp. 680-685 (1970), the purified IL-18 was subjected to SDS-PAGE, resulting in a major band with an IFN-γ inducing activity at a position corresponding to 18,500±3,000 daltons. The IL-18 gave a pI of 4.9±1.0 as determined by conventional chromatofocusing. Conventional analysis using “PROTEIN SEQUENCER MODEL 473A”, an apparatus of Applied Biosystems, Inc., Foster City, USA, revealed that the IL-18 had the amino acid sequence of SEQ ID NO: 9, i.e., the amino acid sequence of SEQ ID NO: 8 where a methionine residue was linked to the N-terminus.
Experiment 2 [0028]
Preparation of Human IL-18 [0029]
According to the method in Japanese Patent Application No. 67,434/96 by the same applicant of the present invention, THP-1 cells, ATCC TIB 202, a human monocyte cell line derived from a male with acute monocytic leukemia, were inoculated to the dorsum subcutaneous tissues of new born hamsters, followed by feeding the hamsters for three weeks. Tumor masses, about 15 g weight each, formed in the subcutaneous tissues of each hamster, were extracted, dispersed in media, and disrupted. The polypeptide obtained from the disrupted cells was purified by immunoaffinity chromatography to obtain a purified human IL-18 in a yield of an about 50 ng/head. [0030]
Similarly, according to the method in Japanese Patent Application No. 67,434/96, the purified human IL-18 was analyzed and determined for biological activity and physicochemical property as indicated below: It was confirmed that culturing human lymphocytes, collected from healthy donors in a conventional manner, in the presence of different concentrations of the human IL-18, resulted in an IL-18 dose-dependent IFN-γ production. This revealed that the human IL-18 has a biological activity of inducing IFN-γ production by lymphocytes as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in [0031] Nature, Vol. 227, pp. 680-685 (1970), the purified human IL-18 was subjected to SDS-PAGE using 2 w/v % dithiothreitol as a reductant, resulting in a major band with an IFN-γ production inducing activity at a position corresponding to 18,000-19,500 daltons. According to the peptide map disclosed in Japanese Patent Application No. 67,434/96, the human IL-18 was treated with clostripain commercialized by Sigma Chemical Company, Missouri, USA, to obtain polypeptide fragments, followed by subjecting the fragments for fractionation to high-performance liquid chromatography (HPLC) using “ODS-120T”, a column commercialized by Tosoh Corporation, Tokyo, Japan, and analyzing the amino acid sequences of the fragments from the N-terminus to reveal the following amino acid sequences of SEQ ID NOs: 10 to 13. These amino acid sequences were completely coincided with amino acids 148-157, 1-13, 45-58, and 80-96 in SEQ ID NO: 6. The data shows that the human IL-18 obtained in Experiment 2 has the amino acid sequence of SEQ ID NO: 6 and all the partial amino acid sequences of SEQ ID NOs: 1 to 5.
Experiment 3 [0032]
Preparation of Functional Equivalents [0033]
According to the method in Japanese Patent Application No. 20,906/97 by the same applicant of the present invention, it was prepared an autonomously-replicable recombinant DNA, pCSHIGIF/MUT35, was linked to a DNA encoding a functional equivalent of human IL-18 where cysteines 38, 68, and 76 in SEQ ID NO: 6 were respectively replaced with serine, serine, and alanine. Dideoxyribonucleotide sequence analysis revealed that as shown in FIG. 2, in the recombinant DNA, DNA IGIF/MUT35 with SEQ ID NO: 14 linked to the downstream of a base sequence encoding a signal peptide of subtype α2b in human interferon-α in the same reading-frame, as reported by K. Henco et al., in [0034] Journal of Molecular Biology, Vol. 185, pp. 227-260 (1985), and had a stop codon for protein synthesis at further downstream. As shown in parallel in SEQ ID NO: 14, the amino acid sequence encoded by the recombinant DNA corresponded to SEQ ID NO: 6 where cysteines 38, 68, and 76 in SEQ ID NO: 6 were respectively replaced with serine, serine, and alanine. The recombinant DNA contained a nucleotide which encodes all the amino acid sequences of SEQ ID NOs: 1 to 4 and the one of SEQ ID NO: 5 where cysteine at amino acid 5 in SEQ ID NO: 5 was replaced with alanine. These amino acid sequences were respectively encoded by nucleotides 46-63, 88-105, 400-420, 151-165, and 214-228 in SEQ ID NO: 14.
According to the method in Japanese Patent Application No. 20,906/97 by the same applicant of the present invention, the recombinant DNA pCSHIGIF/MUT35 was introduced into COS-1 cells, ATCC CRL 1650, an established cell line derived from SV40 transformed African Green monkey kidney, followed by culturing the transformed cells. The produced polypeptide in the culture was purified by immunoaffinity chromatography to obtain a purified functional equivalent of human IL-18 in a yield of about 40 ng/ml culture. According to the method in Japanese Patent Application No. 20,906/97, the purified functional equivalent was analyzed and determined for biological activity and physicochemical property as indicated below: When culturing KG-1 cells, ATCC CCL 246, an established cell line derived from human acute myelogenous leukemia, in the presence of different concentrations of the purified functional equivalent of human IL-18, IFN-γ production was observed depending on the concentration of the IL-18, revealing that the IL-18 has a biological activity of inducing IFN-γ production by KG-1 cells as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in [0035] Nature, Vol. 227, pp. 680-685 (1970), the purified functional equivalent was subjected to SDS-PAGE in the presence of 2 w/v % dithiothreitol as a reductant, resulting in a major band with an IFN-γ production inducing activity at a position corresponding to 18,000-19,500 daltons. Conventional analysis using “PROTEIN SEQUENCER MODEL 473A”, an apparatus of Applied Biosystems, Inc., Foster City, USA, revealed that the N-terminal region of the functional equivalent had the amino acid sequence of SEQ ID NO: 15 which corresponded to the amino acid sequence in the N-terminal region as shown in parallel in SEQ ID NO: 14.
Experiment 4 [0036]
Preparation of Functional Equivalent [0037]
According to the method in Japanese Patent Application No. 20,906/97 by the same applicant of the present invention, it was prepared an autonomously-replicable recombinant DNA, pCSHIGIF/MUT42, which was linked to a DNA encoding for a functional equivalent of human IL-18 where cysteines 38, 68, 76, and 127 in SEQ ID NO: 6 were respectively replaced with serine, serine, alanine, and serine. Dideoxyribonucleotide sequencing revealed that, as shown in FIG. 3, in the recombinant DNA, DNA IGIF/MUT42 with SEQ ID NO: 16 linked to the downstream of a base sequence encoding a signal peptide for subtype α2b of human interferon-α in the same reading frame, as reported by K. Henco et al., in [0038] Journal of Molecular Biology, Vol. 185, pp. 227-260 (1985), and had a stop codon for protein synthesis at further downstream. As shown in parallel in SEQ ID NO: 16, the amino acid sequence encoded by the recombinant DNA corresponded to SEQ ID NO: 6 where cysteines 38, 68, 76, and 127 in SEQ ID NO: 6 were respectively replaced with serine, serine, alanine, and serine. The recombinant DNA contained a nucleotide sequence which encodes all the amino acid sequences of SEQ ID NOs: 1 to 4 and the one of SEQ ID NO: 5 where cysteine 5 in SEQ ID NO: 5 was replaced with alanine. These amino acid sequences were respectively encoded by nucleotides 46-63, 88-105, 400-420, 151-165, and 214-228 in SEQ ID NO: 16.
According to the method in Japanese Patent Application No. 20,906/97 by the same applicant of the present invention, the recombinant DNA pCSHIGIF/MUT42 was introduced into COS-1 cells, followed by culturing the cells. The produced polypeptide in the culture was purified by immunoaffinity chromatography to obtain a purified functional equivalent of human IL-18 in a yield of about 20 ng/ml culture. According to the method in Japanese Patent Application No. 20,906/97, the purified functional equivalent was analyzed and determined for biological activity and physicochemical property as indicated below: When cultured KG-1 cells in the presence of different concentrations of the purified functional equivalent, a dose-dependent IFN-γ production was observed, and this revealed that the functional equivalent has a biological activity of inducing IFN-γ production by KG-1 cells as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in [0039] Nature, Vol. 227, pp. 680-685 (1970), the purified functional equivalent was subjected to SDS-PAGE in the presence of 2 w/v % dithiothreitol as a reductant, resulting in a major band with an IFN-γ inducing activity at a position corresponding to 18,000-19,500 daltons. Conventional analysis using “PROTEIN SEQUENCER MODEL 473A”, an apparatus of Applied Biosystems, Inc., Foster City, USA, revealed that the N-terminal region of the functional equivalent had the amino acid sequence of SEQ ID NO: 15 which completely corresponded to the amino acid sequence in the N-terminal region as shown in parallel in SEQ ID NO: 16.
Experiment 5 [0040]
Preparation of Human IL-18 [0041]
According to the method in Japanese Patent Application No. 185,305/96 by the same applicant of the present invention, an autonomously-replicable recombinant DNA, pBGHuGF, linked to a chromosomal DNA encoding human IL-18, was obtained. Dideoxyribonucleotide sequencing analysis revealed that as shown in FIG. 4, in the recombinant DNA, a chromosomal DNA, which encodes human IL-18, i.e., DNA HuIGIF with SEQ ID NO: 17, was linked to the downstream of a restriction site by a restriction enzyme, Hind III. As shown in SEQ ID NO: 17, the chromosomal DNA HuIGIF consists of 11,464 bp where the exon was fragmented by four introns positioning at nucleotides 83-1,453, 1,466-4,848, 4,984-6,317, and 6,452-11,224. Among the resting nucleotide sequence excluding these introns, nucleotides 3-11,443 from the 5′-terminus are the part that encodes a precursor of human IL-18, and nucleotides 4,866-4,983 are the part that encodes an active human IL-18. The chromosomal DNA contained nucleotides sequences encoding SEQ ID NOs: 1 to 5; these amino acid sequences were respectively encoded by nucleotides 4,911-4,928, 4,953-4,970, 11,372-11,392, 6,350-6,364, and 6,413-6,427 in SEQ ID NO: 17. [0042]
According to the method in Japanese Patent Application No. 185,305/96, the recombinant DNA pBGHuGF was introduced into CHO-K1 cells, ATCC CCL 61, an established cell line derived from Chinese hamster ovary, followed by culturing the cells. The culture supernatant was contacted with a supernatant of cell disruptant prepared from a THP-1 cell culture to produce a polypeptide which was then purified by immunoaffinity chromatography to obtain a purified human IL-18 in a yield of about 15 mg/l culture. According to the method in Japanese Patent Application No. 185,305/96, the polypeptide was analyzed and determined for biological activity and physicochemical property as indicated below: It was confirmed that human lymphocytes, which were collected from a healthy donor, produced IFN-γ depending on the purified human IL-18 concentration when cultured at different concentrations of the human IL-18, revealing that the human IL-18 has a biological activity of inducing IFN-γ production by lymphocytes as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in [0043] Nature, Vol. 227, pp. 680-685 (1970), the purified human IL-18 was subjected to SDS-PAGE in the presence of 2 w/v % dithiothreitol as a reductant, resulting in a major band with an IFN-γ inducing activity at a position corresponding to 18,000-19,500 daltons. The N-terminal region of the human IL-18 contained the amino acid sequence of SEQ ID NO: 15 which completely corresponded to the amino acid sequence in the N-terminal region of SEQ ID NO: 17 for an active IL-18.
Experiment 6 [0044]
Preparation of Mouse IL-18 [0045]
To a 0.5-ml reaction tube were added 8 μl of 25 mM magnesium chloride, 10 μl of 10×PCR buffer, one μl of 25 mM dNTP mix, one μl of 2.5 units/μl of amplitaq DNA polymerase, one ng of a recombinant DNA, which encodes mouse IL-18 having the nucleotide sequence of SEQ ID NO: 18 and the amino acid sequence of SEQ ID NO: 7, prepared from a phage DNA clone according to the method in Japanese Patent Kokai No. 27,189/96, and adequate amounts of a sense and antisense primers having nucleotide sequences represented by 5′-ATAGAATTCAAATGAACTTTGGCCGACTTCACTG-3′ and 5′-ATAAAGCTTCTAACTTTGATGTAAGTT-3′, respectively, which were chemically synthesized based on the amino acid sequences nearness to the N- and C-termini of SEQ ID NO: 7, and the mixture solution was brought up to a volume of 100 μl with sterilized distilled water. The solution thus obtained was subjected in a usual manner to PCR reaction of the following three cycles of successive incubations at 94° C. for one minute, 43° C. for one minute, and 72° C. for one minute, and further 40 cycles of successive incubations at 94° C. for one minute, 60° C. for one minute, and 72° C. for one minute. [0046]
The product obtained by the PCR reaction and “pCR-Script SK (+)”, a plasmid vector commercialized by Stratagene Cloning Systems, California, USA, were in a conventional manner ligated together using a DNA ligase into a recombinant DNA which was then introduced into “XL-1 Blue MRF′Kan”, an [0047] Escherichia coli strain commercialized by Stratagene Cloning Systems, California, USA., to obtain a transformant. The transformant was inoculated to L-broth (pH 7.2) containing 50 μg/ml ampicillin, followed by the incubation at 37° C. for 18 hours under shaking conditions. The culture was centrifuged to obtain the proliferated transformants which were then treated with a conventional alkali-SDS method to isolate a recombinant DNA. A portion of the recombinant DNA isolated was analyzed by dideoxyribonucleotide sequencing, revealing that the recombinant DNA contained restriction sites of Eco RI and Hind III at the 5′- and 3′-termini of SEQ ID NO: 18, respectively, and a DNA containing a methionine codon for initiating polypeptide synthesis and a TAG codon for terminating polypeptide synthesis, which were located in just before and after the N- and C-termini of the amino acid sequence as shown in parallel in SEQ ID NO: 18. The recombinant DNA contained the nucleotide sequences of SEQ ID NOs: 1 to 5. These amino acid sequences were encoded by nucleotides 46-63, 85-102, 394-414, 148-162, and 211-225 in SEQ ID NO: 18.
The remaining portion of the recombinant DNA was in a conventional manner cleaved with restriction enzymes of Eco RI and Hind II, and the resulting 0.1 μg of an Eco RI-Hind III DNA fragments, obtained by using “DNA LIGATION KIT VER 2”, a DNA ligation kit commercialized by Takara Shuzo Co., Ltd., Tokyo, Japan, and 10 ng of pKK223-3, a plasmid vector commercialized by Pharmacia LKB Biotechnology AB, Uppsala, Sweden, which had been cleaved with a restriction enzyme were linked together, by incubating at 16° C. for 30 min to obtain an autonomously-replicable recombinant DNA, pKGFMH2. Using competent cell method, an [0048] Escherichia coli Y1090 strain, ATCC 37197, was transformed using the recombinant DNA pKGFMH2, and the resulting transformant, KGFMH2, was inoculated to L-broth (pH 7.2) containing 50 μg/ml ampicillin, and cultured at 37° C. for 18 hours under shaking conditions. The culture was centrifuged to collect the proliferated transformants, followed by applying a conventional SDS-alkali method to a portion of the transformants to extract the recombinant DNA pKGFMH2. Dideoxyribonucleotide sequencing analysis revealed that, as shown in FIG. 5, KGFMH2 cDNA containing the nucleotide sequence of SEQ ID NO: 18 was linked to the downstream of the Tac promoter in the recombinant DNA pKGFMH2.
Ampicillin was added to L-broth (pH 7.2), which had been sterilized by autoclaving, to give a concentration of 50 μg/ml, cooled to 37° C., and inoculated with the transformant KGFMH2, followed by the culture at 37° C. for 18 hours. Eighteen liters of a fresh preparation of the same culture medium was placed in a 20-l jar fermenter, similarly sterilized as above, admixed with ampicillin, cooled to 37° C., and inoculated with one v/v % of the seed culture obtained in the above, followed by the culture at 37° C. for 8 hours under aeration-agitation conditions. The resulting culture was centrifuged to collect the cultured cells which were then suspended in a mixture solution (pH 7.3) containing 150 mM sodium chloride, 16 mM disodium hydrogenphosphate, and 4 mM sodium dihydrogenphosphate, disrupted by ultrasonication, and centrifuged to remove cell disruptant, and this yielded an about two liters of a supernatant. [0049]
To an about two liters of the supernatant was added 10 mM phosphate buffer (pH 7.3) containing ammonium sulfate to give a 40% ammonium saturation. The resulting sediment was removed by centrifugation, and the supernatant was mixed with ammonium sulfate to give an 85% ammonium saturation, allowed to stand at 4° C. for 18 hours, and centrifuged at about 8,000 rpm for 30 min to obtain a newly formed sediment. The sediment thus obtained was dissolved in 10 mM phosphate buffer (pH 6.6) containing 1.5 M ammonium sulfate to give a total volume of about 1,300 ml, and the solution was filtered, and fed to a column packed with about 800 ml of “PHENYL SEPHAROSE CL-6B”, a gel commercialized by Pharmacia LKB Biotechnology AB, Uppsala, Sweden, followed by washing the column with a fresh preparation of the same buffer and feeding to the column a linear gradient buffer of ammonium sulfate decreasing from 1.5 M to 0 M in 10 mM phosphate buffer (pH 6.6) at an SV (space velocity) 1.5. Fractions eluted at around 1 M ammonium sulfate were pooled, concentrated using a membrane filter, and dialyzed against 10 mM phosphate buffer (pH 6.5) at 4° C. for 18 hours. The dialyzed solution was fed to a column packed with about 55 ml of “DEAE-5PW”, a gel commercialized by Pharmacia LKB Biotechnology AB, Uppsala, Sweden, which had been equilibrated with 10 mM phosphate buffer (pH 6.5). The column was washed with a fresh preparation of the same buffer, and fed with a linear gradient buffer of sodium chloride increasing from 0 M to 0.5 M in 10 mM phosphate buffer (pH 6.5) at SV 5.5, followed by collecting fractions eluted at around 0.2 M sodium chloride. Thereafter, the fractions were pooled and concentrated similarly as above up to give an about nine milliliters, followed by dialyzing the concentrate against PBS (phosphate buffered saline) at 4° C. for 18 hours, and feeding the dialyzed solution to a column packed with “SUPERDEX 75”, a gel commercialized by Pharmacia LKB Biotechnology AB, Uppsala, Sweden, which had been equilibrated with a fresh preparation of the same PBS. The column was fed with a fresh preparation of the same PBS to collect fractions with an IFN-γ inducing activity, and the fractions were pooled and concentrated with a membrane filter to obtain a purified mouse IL-18 in a yield of about 350 μg/l culture. [0050]
According to the method in Japanese Patent Kokai No. 27,189/96, the purified mouse IL-18 was analyzed and determined for biological activity and physicochemical property as indicated below: Culturing mouse spleen cells, collected by a conventional manner, under different concentrations of the mouse IL-18 resulted in an IFN-γ production depending on the concentrations of the mouse IL-18, and this revealed that the mouse IL-18 has an activity of inducing IFN-y production by spleen cells as an immunocompetent cell. In accordance with the method as reported by U. K. Laemmli in [0051] Nature, Vol. 227, pp. 680-685 (1970), the purified human IL-18 was subjected to SDS-PAGE under non-reducing conditions, resulting in a major band with an IFN-γ inducing activity at a position corresponding to 19,000±5,000 daltons. The N-terminal region of the mouse IL-18 contained the amino acid sequence of SEQ ID NO: 19 which corresponded to the N-terminal region of SEQ ID NO: 18.
With reference to Experiment 7, the biological activity of the IL-18 according to the present invention will be described in more detail, and Experiment 8 describes the cytotoxicity of the IL-18: [0052]
Experiment 7 [0053]
Biological Activity [0054]
Experiment 7-1 [0055]
Induction of GM-CSF Production [0056]
Using a heparinized syringe, blood was collected from a healthy volunteer and diluted two fold with serum-free RPMI 1640 medium (pH 7.4). The diluent was overlaid on a ficoll and centrifuged, and the collected lymphocytes were washed with RPMI 1640 medium (pH 7.4) supplemented with 10 v/v % fetal calf serum, and suspended in a fresh preparation of the same medium to give a cell density of 1×10[0057] ⁶cells/ml, followed by distributing the cell suspension to a 12-well microplate by two ml/well.
Using RPMI 1640 medium (pH 7.4) supplemented with 10 v/v % fetal calf serum, an IL-18 preparation obtained by the method in Experiment 1 was prepared into a one μg/ml solution which was then distributed to the above microplate by 20-200 μl/well. To the microplate was further added a fresh preparation of the same buffer, supplemented with 500 μl/ml of Concanavalin A, by 10 μl/well, followed by the incubation at 37° C. for 48 hours in a 5 v/v % CO[0058] ₂incubator. After completion of the culture, supernatants in each well were sampled by 0.1 ml/well, and determined for GM-CSF content using a conventional enzyme immunoassay. In parallel, a culture system free of IL-18 as a control was provided and treated similarly as above. The data is in Table 1:

TABLE 1

IL-18* GM-CSF yield

(nM) (pg/ml)

0 510

0.7 2,150

2.8 3,050

5.6 3,950
The results in Table 1 indicate that lymphocytes as an immunocompetent cell produced GM-CSF depending on the concentration of IL-18 when contacted with IL-18 in the presence of Concanavalin A as a cofactor. It was also confirmed that all of the IL-18 preparations and functional equivalents thereof, which were obtained by the methods in Experiments 2 to 5, induced GM-CSF production even when used alone similarly as above. An IL-18 preparation obtained by the method in Experiment 6 was tested in accordance with Experiment 7-1 except that the human lymphocytes used in the experiment were replaced with spleen cells prepared from mouse by a conventional manner, revealing that the IL-18 preparation also induced GM-CSF production. [0059]
Experiment 7-2 [0060]
Inhibition of Osteoclast Formation [0061]
Experiment 7-2(a) [0062]
As reported by T. J. Martin and K. W. Ng in [0063] Journal of Cellular Biochemistry, Vol. 56, pp. 357-366 (1994), it is considered requisite for contacting osteoclastic precursor cells, derived from hematopoietic stem cells, with osteoblasts or bone marrow stromas to generally differentiate osteoclastic precursor cells into mature osteoclasts. As described by G. D. Roodman in Endocrine Reviews, Vol. 17, No. 4, pp. 308-332 (1996), it is generally recognized that osteoclasts have characters of multinucleated cells, tartaric acid-resistant acid phosphatase (hereinafter abbreviated as “TRAP”) activity, and a calcitonin receptor. In a co-culture system of osteoblasts and bone marrow cells as reported by Nobuyuki UDAGAWA et al., in Journal of Experimental Medicine, Vol. 182, pp. 1,461-1,468 (1995), these cells respond to factors such as 1α,25-dihydroxyvitamin D₃, prostaglandin E₂, adrenocortical hormone, interleukin 1, interleukin 6, and interleukin 11, to form osteoclast-like cells (hereinafter may be abbreviated as “OCL”). The formed OCL has characters of osteoclasts in vivo. Therefore, the co-culture system well reflects in vitro the processes of osteoclast formation in vivo. Using this system, experiments for osteoclast formation and osteoclastgenic inhibitory agents can be carried out.
The osteoclastgenic inhibitory activity of the IL-18 according to the present invention was studied using the above co-culture system. The osteoblasts used in this experiment were prepared in a conventional manner by treating a newborn mouse calvaria with 0.1 w/v % collagenase commercialized by Worthington Biochemical Co., Freefold, Australia, and 0.2 w/v % dispase commercialized by Godo Shusei Co., Ltd., Tokyo, Japan. The bone marrow cells were prepared from a mature mouse in a conventional manner. As a negative control, 2×10[0064] ⁴cells of a primary cell culture of osteoblasts and 5×10⁵cells of bone marrow cells were co-cultured in each well of a 48-well microplate containing 0.4 ml/well of α-MEM medium supplemented with 10 v/v % fetal calf serum (hereinafter designated as “Medium” throughout Experiment 4-2) at 37° C. for seven days in a 5 v/v % CO₂incubator. As a positive control, the above two-types of cells were co-cultured similarly as in the negative control except that they were cultured in other wells containing 10⁻⁸M of 1α,25-dihydroxyvitamin D₃commercialized by Wako Pure Chemicals, Tokyo, Japan, and 10⁻⁷M of prostaglandin E₂commercialized by Sigma Chemical Company, Missouri, USA. The aforesaid two-types of cells were co-cultured similarly as in the positive control except that they were cultured in other wells containing 1α,25-dihydroxyvitamin D₃commercialized by Wako Pure Chemicals, Tokyo, Japan, and prostaglandin E₂commercialized by Sigma Chemical Company, Missouri, USA., in the same concentrations as used in the positive control, and a concentration of 0.01-10 ng/ml of an IL-18 preparation prepared by the method in Experiment 6. In every co-culture system, the media in each well were replaced with fresh preparations of the same media used in the co-culture systems on the 3rd day after the initiation of each culture. According to the method by Nobuyuki UDAGAWA in Journal of Experimental Medicine, Vol. 182, pp. 1,461-1,468 (1995), the cells on the 6th day after the initiation of each culture were fixed and stained based on TRAP activity, followed by counting the stained cells (hereinafter called “TRAP-positive cells”) per well. Throughout Experiment 4-2, quadruplet wells under the same conditions were provided for each co-culture system, and the mean value for the TRAP-positive cells per well in each system was calculated. The results are in Table 2:

TABLE 2

IL-18 Osteoclastgenic

(ng/ml) formation factor*1 Number of TRAP-positive cells per well*2

0 − 2

0 + 110

0.01 + 114

0.1 + 111

0.5 + 106

1 + 63

2 + 29

4 + 12

8 + 2

10 + 2
As shown in Table 2, the formation of TRAP-positive cells was not substantially observed in the negative control, but the distinct formation was observed in the positive control. In the co-culture systems, i.e., the positive control supplemented additionally with IL-18, the formation of TRAP-positive cells was inhibited depending on the concentration of IL-18, and the maximum inhibition, i.e., a level equal to that in the negative control, was found at eight ng/ml or more of IL-18. These data strongly indicates that IL-18 has a concrete activity of inhibiting OCL formation in vitro and also inhibits osteoclast formation. [0065]
Experiment 7-2(b) [0066]
As described hereinbefore, it was confirmed that there exist factors that induce the formation of osteoclast-like cells in the co-culture systems used throughout Experiment 7-2. Therefore, in this Experiment 7-2(b), it was studied whether the inhibitory activity of IL-18 on osteoclast formation observed in Experiment 7-2(a) was specific to some factors or not; the osteoclast-like cells were cultured by the same method as used in the negative control in Experiment 7-2(a) except for using a medium supplemented with 10[0067] ⁻⁸M 1α,25-dihydroxyvitamin D₃, 10⁻⁷M prostaglandin E₂, 200 ng/ml parathyroid hormone, 100 ng/ml interleukin 1, or 20 ng/ml interleukin 11. These culture systems were for positive controls. In parallel, the cells were cultured in other wells by the same method used in the positive controls except for using a medium containing 10 ng/ml of an IL-18 preparation obtained by the method in Experiment 6, in addition to any one of the above factors at the same concentration. After completion of the cultures, TRAP-positive cells in each well were counted, and the numbers were compared similarly as in Experiment 7-2(a). The results are in Table 3:

TABLE 3

Osteoclast formation factor*1 Number of

(concentration) IL-18*2 TRAP-positive cells per well*3

D₃ (10⁻⁸M) − 94

+ 3

PGE₂ (10⁻⁷M) − 77

+ 3

PTH (200 ng/ml) − 63

+ 3

IL-11 (100 ng/ml) − 84

+ 3

IL-1 (20 ng/ml) − 71

+ 3
As shown in Table 3, a distinct formation of TRAP-positive cells was observed in every positive control, but the formation was almost completely inhibited in the presence of IL-18. This strongly indicates that IL-18 has a wide and general activity of inhibiting osteoclast formation independently of osteoclast-formation-related factors. [0068]
Experiment 7-2(c) [0069]
It was studied whether the osteoclastgenic inhibition by IL-18, confirmed in Experiments 7-2(a) and 7-2(b), was caused by the action of the IL-18-induced GM-CSF. For positive and negative controls, the same co-culture systems employed in Experiment 7-2(a) were used. Using other wells, the co-culture of osteoblasts and bone marrow cells was carried out similarly as the method used for the positive controls except for using a medium supplemented with 1α,25-dihydroxyvitamin D[0070] ₃and prostaglandin E₂at the same concentrations used in the positive control, and with (i) 10 μg/ml of an anti-mouse GM-CSF polyclonal antibody commercialized by R&D Systems, Minnesota, USA, (ii) 10 ng/ml of an IL-18 preparation obtained by the method in Experiment 6, (iii) (ii) plus 10 μg/ml of an anti-mouse polyclonal antibody, (iv) 0.1 ng/ml of a mouse GM-CSF commercialized by R&D Systems, Minnesota, USA, or (v) (iv) plus 10 μg/ml of an anti-mouse GM-CSF polyclonal antibody. After completion of the culture, TRAP-positive cells in each well were counted, and the numbers were compared similarly as in Experiment 7-2(a). The data is shown in Table 4 where the symbols “i” to “v” coincide with those used in the co-culture systems other than the control systems.

TABLE 4

Culture Osteoclastgenic Anti-GM-CSF Number of TRAP-positive

system*1 factor*2 IL-18*3 GM-CSF*4 antibody*5 cells per well*6

N − − − − 3

p + − − − 122

i + − − + 112

ii + + − − 3

iii + + − + 111

iv + − + − 4

v + − + + 106
As shown in Table 4, the formation of TRAP-positive cells was almost completely inhibited by IL-18, cf., the co-culture system (ii), but the inhibition was almost completely inhibited by the addition of the anti-mouse polyclonal antibody, cf., the co-culture system (iii). Mouse GM-CSF exhibited an activity of inhibiting the formation of TRAP-positive cells similar to IL-18, cf., the co-culture system (iv), and the inhibition was almost completely inhibited by the addition of the anti-mouse GM-CSF polyclonal antibody, cf., the co-culture system (v). The sole use of the anti-mouse GM-CSF polyclonal antibody gave no influence on the formation of TRAP-positive cells, cf., the co-culture system (i). These data strongly indicates that the osteoclastgenic inhibition by IL-18 was due to the action of the IL-18-induced GM-CSF. [0071]
Experiment 8 [0072]
Acute Toxicity Test [0073]
Eight-week-old mice were in a conventional manner injected percutaneously, orally, or intraperitoneally with either of IL-18 preparations obtained by the methods in Experiments 1 to 6. The results showed that these IL-18 preparations had an LD[0074] ₅₀of about one mg/kg or more in mice independent of the route of administration. The data evidences that IL-18 can be incorporated into pharmaceuticals for warm-blooded animals in general and including humans without causing no serious side effects.
As described in [0075] Nikkei Biotechnology Annual Report 1996, pp. 498-499 (1995), published by Nikkei BP Publisher, Tokyo, Japan (1995), the IL-18-induced GM-CSF has not yet been clinically used in Japan, but applied clinically in USA and Europe. The fact would show that IL-18 has substantially no serious side effects. These facts indicate that the osteoclastgenic inhibitory agent according to the present invention can be successively administered to warm-blooded animals in general and including humans to induce osteoclast formation and exert a satisfactory therapeutic and/or prophylactic effect on osteoclast-related diseases without causing serious side effects.
The following Examples describe the present osteoclastgenic inhibitory agent according to the present invention: [0076]

EXAMPLE 1

Liquid [0077]
Either of IL-18 preparations, obtained by the methods in Experiments 1 to 6, was dissolved in physiological saline containing one w/v % human serum albumin as a stabilizer to give a concentration of two mg/ml of the IL-18 preparation. The resulting solutions were in a conventional manner membrane filtered for sterilization into liquids. [0078]
The liquids have a satisfactory stability and can be arbitrarily used as ingredients for cell culture and agents in the form of an injection, ophthalmic solution, or collunarium for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0079]

EXAMPLE 2

Dry Agent [0080]
Fifty milligrams of either of IL-18 preparations, obtained by the methods in Experiments 1 to 6, was dissolved in 100 ml of physiological saline containing one w/v % purified gelatin as a stabilizer. The solutions thus obtained were in a conventional manner membrane filtered for sterilization, distributed to vials by one milliliter, lyophilized, and sealed with caps. [0081]
The products have a satisfactory stability and can be arbitrarily used as ingredients for cell culture and agents in the form of a dry injection for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0082]

EXAMPLE 3

Dry Agent [0083]
Fifty milligrams of either of IL-18 preparations, obtained by the methods in Experiments 1 to 6, was dissolved in 100 ml of physiological saline containing one w/v % trehalose as a stabilizer. The solutions were in a conventional manner membrane filtered for sterilization, distributed to vials by one milliliter, lyophilized, and sealed with caps. [0084]
The products have a satisfactory stability and can be arbitrarily used as ingredients for cell culture and agents in the form of a dry injection for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0085]

EXAMPLE 4

Ointment [0086]
“HIVIS WAKO GEL® 104”, a carboxyvinylpolymer commercialized by Wako Pure Chemical Industries, Ltd., Tokyo, Japan, and a high-purity trehalose were dissolved in a sterilized distilled water to give respective concentrations of 1.4 w/w % and 2.0 w/w %, and the solution was mixed to homogeneity with either of IL-18 preparations obtained by the methods in Experiments 1 to 6, and adjusted to pH 7.2 to obtain a paste containing about one mg of an IL-18 preparation per g of the product. [0087]
Each product thus obtained has a satisfactory spreadability and stability and can be arbitrarily used as an agent in the form of an ointment for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0088]

EXAMPLE 5

Tablet [0089]
“FINETOSE®”, an anhydrous crystalline a-maltose powder commercialized by Hayashibara Biochemical Laboratories, Inc., Okayama, Japan, was mixed to homogeneity with either of IL-18 preparations, obtained by the methods in Experiments 1 to 6, and “LUMIN” or 1-1′-1″-trihepthyl-11-chinolyl(4)·4·4′-penthamethinchynocyanine-1,1″-dijodide. The mixtures were in a conventional manner tabletted to obtain tablets, about 200 mg weight each, containing an about two milligrams of either of the IL-18 preparations and an about two milligrams of LUMIN per tablet. [0090]
The products have a satisfactory swallowability, stability, and cell-activating activity and can be arbitrarily used as agents in the form of a tablet for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0091]
As described above, the osteoclastgenic inhibitory agent according to the present invention effectively inhibits osteoclast formation. Therefore, the agent can be arbitrarily used as an ingredient for cell culture and agents for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc. [0092]
Thus the present invention with these useful activities and functions is a significant invention that would greatly contribute to this field. [0093]
While there has been described what is at present considered to be the preferred embodiments of the invention, it will be understood the various modifications may be made therein, and it is intended to cover in the appended claims all such modifications as fall within the true spirits and scope of the invention. [0094]
1 28 6 amino acids amino acid linear peptide internal fragment 1 Asn Asp Gln Val Leu Phe 1 5 6 amino acids amino acid linear internal fragment 2 Phe Glu Asp Met Thr Asp 1 5 7 amino acids amino acid linear peptide internal fragment 3 Phe Lys Leu Ile Leu Lys Lys 1 5 5 amino acids amino acid linear internal fragment 4 Met Tyr Lys Asp Ser 1 5 5 amino acids amino acid linear internal fragment 5 Ser Thr Leu Ser Cys 1 5 157 amino acids amino acid linear peptide 6 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 7 Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn 1 5 10 15 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met 20 25 30 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile 35 40 45 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser 50 55 60 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile 65 70 75 80 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser 85 90 95 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu 100 105 110 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu 115 120 125 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp 130 135 140 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser 145 150 155 471 base pairs nucleic acid double linear cDNA human liver mat peptide 1..471 E 8 TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 ATG ACT GAT TCT GAC TGT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 TCT GTG AAG TGT GAG AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT 240 Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA 288 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TGT GAA 384 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 11 amino acids amino acid linear peptide N-terminal fragment 9 Met Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser 1 5 10 10 amino acids amino acid linear peptide C-terminal fragment 10 Ser Ile Met Phe Thr Val Gln Asn Glu Asp 1 5 10 13 amino acids amino acid linear peptide N-terminal fragment 11 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg 1 5 10 14 amino acids amino acid linear peptide internal fragment 12 Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg 1 5 10 17 amino acids amino acid linear peptide internal fragment 13 Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 1 5 10 15 471 base pairs nucleic acid double linear cDNA mat peptide 1..471 S 14 TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 ATG ACT GAT TCT GAC TCT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC GCT GAG AAC AAA ATT 240 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile 65 70 75 80 ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA 288 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TGT GAA 384 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 10 amino acids amino acid linear peptide N-terminal fragment 15 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser 1 5 10 471 base pairs nucleic acid double linear cDNA mat peptide 1..471 S 16 TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 ATG ACT GAT TCT GAC TCT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC GCT GAG AAC AAA ATT 240 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile 65 70 75 80 ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA 288 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TCT GAA 384 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu 115 120 125 AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 11464 base pairs nucleic acid double linear genomic DNA human placenta 5 UTR 1..3 E (A) NAME/KEY leader peptide (B) LOCATION 4..82 (C) IDENTIFICATION METHOD S (A) NAME/KEY intron (B) LOCATION 83..1453 (C) IDENTIFICATION METHOD E (A) NAME/KEY leader peptide (B) LOCATION 1454..1465 (C) IDENTIFICATION METHOD S (A) NAME/KEY intron (B) LOCATION 1466..4848 (C) IDENTIFICATION METHOD E (A) NAME/KEY leader peptide (B) LOCATION 4849..4865 (C) IDENTIFICATION METHOD S (A) NAME/KEY mat peptide (B) LOCATION 4866..4983 (C) IDENTIFICATION METHOD S (A) NAME/KEY intron (B) LOCATION 4984..6317 (C) IDENTIFICATION METHOD E (A) NAME/KEY mat peptide (B) LOCATION 6318..6451 (C) IDENTIFICATION METHOD S (A) NAME/KEY intron (B) LOCATION 6452..11224 (C) IDENTIFICATION METHOD E (A) NAME/KEY mat peptide (B) LOCATION 11225..11443 (C) IDENTIFICATION METHOD S (A) NAME/KEY 3 UTR (B) LOCATION 11444..11464 (C) IDENTIFICATION METHOD E 17 AAG ATG GCT GCT GAA CCA GTA GAA GAC AAT TGC ATC AAC TTT GTG GCA 48 Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala -35 -30 -25 ATG AAA TTT ATT GAC AAT ACG CTT TAC TTT ATA G GTAAGG CTAATGCCAT 98 Met Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala -20 -15 -10 AGAACAAATA CCAGGTTCAG ATAAATCTAT TCAATTAGAA AAGATGTTGT GAGGTGAACT 158 ATTAAGTGAC TCTTTGTGTC ACCAAATTTC ACTGTAATAT TAATGGCTCT TAAAAAAATA 218 GTGGACCTCT AGAAATTAAC CACAACATGT CCAAGGTCTC AGCACCTTGT CACACCACGT 278 GTCCTGGCAC TTTAATCAGC AGTAGCTCAC TCTCCAGTTG GCAGTAAGTG CACATCATGA 338 AAATCCCAGT TTTCATGGGA AAATCCCAGT TTTCATTGGA TTTCCATGGG AAAAATCCCA 398 GTACAAAACT GGGTGCATTC AGGAAATACA ATTTCCCAAA GCAAATTGGC AAATTATGTA 458 AGAGATTCTC TAAATTTAGA GTTCCGTGAA TTACACCATT TTATGTAAAT ATGTTTGACA 518 AGTAAAAATT GATTCTTTTT TTTTTTTTCT GTTGCCCAGG CTGGAGTGCA GTGGCACAAT 578 CTCTGCTCAC TGCAACCTCC ACCTCCTGGG TTCAAGCAAT TCTCCTGCCT CAGCCTTCTG 638 AGTAGCTGGG ACTACAGGTG CATCCCGCCA TGCCTGGCTA ATTTTTGGGT ATTTTTACTA 698 GAGACAGGGT TTTGGCATGT TGTCCAGGCT GGTCTTGGAC TCCTGATCTC AGATGATCCT 758 CCTGGCTCGG GCTCCCAAAG TGCTGGGATT ACAGGCATGA ACCACCACAC ATGGCCTAAA 818 AATTGATTCT TATGATTAAT CTCCTGTGAA CAATTTGGCT TCATTTGAAA GTTTGCCTTC 878 ATTTGAAACC TTCATTTAAA AGCCTGAGCA ACAAAGTGAG ACCCCATCTC TACAAAAAAC 938 TGCAAAATAT CCTGTGGACA CCTCCTACCT TCTGTGGAGG CTGAAGCAGG AGGATCACTT 998 GAGCCTAGGA ATTTGAGCCT GCAGTGAGCT ATGATCCCAC CCCTACACTC CAGCCTGCAT 1058 GACAGTAGAC CCTGACACAC ACACACAAAA AAAAACCTTC ATAAAAAATT ATTAGTTGAC 1118 TTTTCTTAGG TGACTTTCCG TTTAAGCAAT AAATTTAAAA GTAAAATCTC TAATTTTAGA 1178 AAATTTATTT TTAGTTACAT ATTGAAATTT TTAAACCCTA GGTTTAAGTT TTATGTCTAA 1238 ATTACCTGAG AACACACTAA GTCTGATAAG CTTCATTTTA TGGGCCTTTT GGATGATTAT 1298 ATAATATTCT GATGAAAGCC AAGACAGACC CTTAAACCAT AAAAATAGGA GTTCGAGAAA 1358 GAGGAGTAGC AAAAGTAAAA GCTAGAATGA GATTGAATTC TGAGTCGAAA TACAAAATTT 1418 TACATATTCT GTTTCTCTCT TTTTCCCCCT CTTAG CT GAA GAT GAT G GTAAA 1470 Ala Glu Asp Asp Glu -10 GTAGAAATGA ATTTATTTTT CTTTGCAAAC TAAGTATCTG CTTGAGACAC ATCTATCTCA 1530 CCATTGTCAG CTGAGGAAAA AAAAAAATGG TTCTCATGCT ACCAATCTGC CTTCAAAGAA 1590 ATGTGGACTC AGTAGCACAG CTTTGGAATG AAGATGATCA TAAGAGATAC AAAGAAGAAC 1650 CTCTAGCAAA AGATGCTTCT CTATGCCTTA AAAAATTCTC CAGCTCTTAG AATCTACAAA 1710 ATAGACTTTG CCTGTTTCAT TGGTCCTAAG ATTAGCATGA AGCCATGGAT TCTGTTGTAG 1770 GGGGAGCGTT GCATAGGAAA AAGGGATTGA AGCATTAGAA TTGTCCAAAA TCAGTAACAC 1830 CTCCTCTCAG AAATGCTTTG GGAAGAAGCC TGGAAGGTTC CGGGTTGGTG GTGGGGTGGG 1890 GCAGAAAATT CTGGAAGTAG AGGAGATAGG AATGGGTGGG GCAAGAAGAC CACATTCAGA 1950 GGCCAAAAGC TGAAAGAAAC CATGGCATTT ATGATGAATT CAGGGTAATT CAGAATGGAA 2010 GTAGAGTAGG AGTAGGAGAC TGGTGAGAGG AGCTAGAGTG ATAAACAGGG TGTAGAGCAA 2070 GACGTTCTCT CACCCCAAGA TGTGAAATTT GGACTTTATC TTGGAGATAA TAGGGTTAAT 2130 TAAGCACAAT ATGTATTAGC TAGGGTAAAG ATTAGTTTGT TGTAACAAAG ACATCCAAAG 2190 ATACAGTAGC TGAATAAGAT AGAGAATTTT TCTCTCAAAG AAAGTCTAAG TAGGCAGCTC 2250 AGAAGTAGTA TGGCTGGAAG CAACCTGATG ATATTGGGAC CCCCAACCTT CTTCAGTCTT 2310 GTACCCATCA TCCCCTAGTT GTTGATCTCA CTCACATAGT TGAAAATCAT CATACTTCCT 2370 GGGTTCATAT CCCAGTTATC AAGAAAGGGT CAAGAGAAGT CAGGCTCATT CCTTTCAAAG 2430 ACTCTAATTG GAAGTTAAAC ACATCAATCC CCCTCATATT CCATTGACTA GAATTTAATC 2490 ACATGGCCAC ACCAAGTGCA AGGAAATCTG GAAAATATAA TCTTTATTCC AGGTAGCCAT 2550 ATGACTCTTT AAAATTCAGA AATAATATAT TTTTAAAATA TCATTCTGGC TTTGGTATAA 2610 AGAATTGATG GTGTGGGGTG AGGAGGCCAA AATTAAGGGT TGAGAGCCTA TTATTTTAGT 2670 TATTACAAGA AATGATGGTG TCATGAATTA AGGTAGACAT AGGGGAGTGC TGATGAGGAG 2730 CTGTGAATGG ATTTTAGAAA CACTTGAGAG AATCAATAGG ACATGATTTA GGGTTGGATT 2790 TGGAAAGGAG AAGAAAGTAG AAAAGATGAT GCCTACATTT TTCACTTAGG CAATTTGTAC 2850 CATTCAGTGA AATAGGGAAC ACAGGAGGAA GAGCAGGTTT TGGTGTATAC AAAGAGGAGG 2910 ATGGATGACG CATTTCGTTT TGGATCTGAG ATGTCTGTGG AACGTCCTAG TGGAGATGTC 2970 CACAAACTCT TCTACATGTG GTTCTGAGTT CAGGACACAG ATTTGGGCTG GAGATAGAGA 3030 TATTGTAGGC TTATACATAG AAATGGCATT TGAATCTATA GAGATAAAAA GACACATCAG 3090 AGGAAATGTG TAAAGTGAGA GAGGAAAAGC CAAGTACTGT GCTGGGGGGA ATACCTACAT 3150 TTAAAGGATG CAGTAGAAAG AAGCTAATAA ACAACAGAGA GCAGACTAAC CAAAAGGGGA 3210 GAAGAAAAAC CAAGAGAATT CCACCGACTC CCAGGAGAGC ATTTCAAGAT TGAGGGGATA 3270 GGTGTTGTGT TGAATTTTGC AGCCTTGAGA ATCAAGGGCC AGAACACAGC TTTTAGATTT 3330 AGCAACAAGG AGTTTGGTGA TCTCAGTGAA AGCAGCTTGA TGGTGAAATG GAGGCAGAGG 3390 CAGATTGCAA TGAGTGAAAC AGTGAATGGG AAGTGAAGAA ATGATACAGA TAATTCTTGC 3450 TAAAAGCTTG GCTGTTAAAA GGAGGAGAGA AACAAGACTA GCTGCAAAGT GAGATTGGGT 3510 TGATGGAGCA GTTTTAAATC TCAAAATAAA GAGCTTTGTG CTTTTTTGAT TATGAAAATA 3570 ATGTGTTAAT TGTAACTAAT TGAGGCAATG AAAAAAGATA ATAATATGAA AGATAAAAAT 3630 ATAAAAACCA CCCAGAAATA ATGATAGCTA CCATTTTGAT ACAATATTTC TACACTCCTT 3690 TCTATGTATA TATACAGACA CAGAAATGCT TATATTTTTA TTAAAAGGGA TTGTACTATA 3750 CCTAAGCTGC TTTTTCTAGT TAGTGATATA TATGGACATC TCTCCATGGC AACGAGTAAT 3810 TGCAGTTATA TTAAGTTCAT GATATTTCAC AATAAGGGCA TATCTTTGCC CTTTTTATTT 3870 AATCAATTCT TAATTGGTGA ATGTTTGTTT CCAGTTTGTT GTTGTTATTA ACAATGTTCC 3930 CATAAGCATT CCTGTACACC AATGTTCACA CATTTGTCTG ATTTTTTCTT CAGGATAAAA 3990 CCCAGGAGGT AGAATTGCTG GGTTGATAGA AGAGAAAGGA TGATTGCCAA ATTAAAGCTT 4050 CAGTAGAGGG TACATGCCGA GCACAAATGG GATCAGCCCT AGATACCAGA AATGGCACTT 4110 TCTCATTTCC CCTTGGGACA AAAGGGAGAG AGGCAATAAC TGTGCTGCCA GAGTTAAATT 4170 TGTACGTGGA GTAGCAGGAA ATCATTTGCT GAAAATGAAA ACAGAGATGA TGTTGTAGAG 4230 GTCCTGAAGA GAGCAAAGAA AATTTGAAAT TGCGGCTATC AGCTATGGAA GAGAGTGCTG 4290 AACTGGAAAA CAAAAGAAGT ATTGACAATT GGTATGCTTG TAATGGCACC GATTTGAACG 4350 CTTGTGCCAT TGTTCACCAG CAGCACTCAG CAGCCAAGTT TGGAGTTTTG TAGCAGAAAG 4410 ACAAATAAGT TAGGGATTTA ATATCCTGGC CAAATGGTAG ACAAAATGAA CTCTGAGATC 4470 CAGCTGCACA GGGAAGGAAG GGAAGACGGG AAGAGGTTAG ATAGGAAATA CAAGAGTCAG 4530 GAGACTGGAA GATGTTGTGA TATTTAAGAA CACATAGAGT TGGAGTAAAA GTGTAAGAAA 4590 ACTAGAAGGG TAAGAGACCG GTCAGAAAGT AGGCTATTTG AAGTTAACAC TTCAGAGGCA 4650 GAGTAGTTCT GAATGGTAAC AAGAAATTGA GTGTGCCTTT GAGAGTAGGT TAAAAAACAA 4710 TAGGCAACTT TATTGTAGCT ACTTCTGGAA CAGAAGATTG TCATTAATAG TTTTAGAAAA 4770 CTAAAATATA TAGCATACTT ATTTGTCAAT TAACAAAGAA ACTATGTATT TTTAAATGAG 4830 ATTTAATGTT TATTGTAG AA AAC CTG GAA TCA GAT TAC TTT GGC AAG CTT 4880 Glu Asn Leu Glu Ser Asp Tyr Phe Gly Lys Leu -5 1 5 GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT GAC CAA GTT CTC TTC 4928 Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn Asp Gln Val Leu Phe 10 15 20 ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT ATG ACT GAT TCT GAC 4976 Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp Met Thr Asp Ser Asp 25 30 35 TGT AGA G GTATTTTTT TTAATTCGCA AACATAGAAA TGACTAGCTA CTTCTTCCCA 5032 Cys Arg Asp 40 TTCTGTTTTA CTGCTTACAT TGTTCCGTGC TAGTCCCAAT CCTCAGATGA AAAGTCACAG 5092 GAGTGACAAT AATTTCACTT ACAGGAAACT TTATAAGGCA TCCACGTTTT TTAGTTGGGG 5152 TAAAAAATTG GATACAATAA GACATTGCTA GGGGTCATGC CTCTCTGAGC CTGCCTTTGA 5212 ATCACCAATC CCTTTATTGT GATTGCATTA ACTGTTTAAA ACCTCTATAG TTGGATGCTT 5272 AATCCCTGCT TGTTACAGCT GAAAATGCTG ATAGTTTACC AGGTGTGGTG GCATCTATCT 5332 GTAATCCTAG CTACTTGGGA GGCTCAAGCA GGAGGATTGC TTGAGGCCAG GACTTTGAGG 5392 CTGTAGTACA CTGTGATCGT ACCTGTGAAT AGCCACTGCA CTCCAGCCTG GGTGATATAC 5452 AGACCTTGTC TCTAAAATTA AAAAAAAAAA AAAAAAAAAC CTTAGGAAAG GAAATTGATC 5512 AAGTCTACTG TGCCTTCCAA AACATGAATT CCAAATATCA AAGTTAGGCT GAGTTGAAGC 5572 AGTGAATGTG CATTCTTTAA AAATACTGAA TACTTACCTT AACATATATT TTAAATATTT 5632 TATTTAGCAT TTAAAAGTTA AAAACAATCT TTTAGAATTC ATATCTTTAA AATACTCAAA 5692 AAAGTTGCAG CGTGTGTGTT GTAATACACA TTAAACTGTG GGGTTGTTTG TTTGTTTGAG 5752 ATGCAGTTTC ACTCTGTCAC CCAGGCTGAA GTGCAGTGCA GTGCAGTGGT GTGATCTCGG 5812 CTCACTACAA CCTCCACCTC CCACGTTCAA GCGATTCTCA TGCCTCAGTC TCCCGAGTAG 5872 GTGGGATTAC AGGCATGCAC CACTTACACC CGGCTAATTT TTGTATTTTT AGTAGAGCTG 5932 GGGTTTCACC ATGTTGGCCA GGCTGGTCTC AAACCCCTAA CCTCAAGTGA TCTGCCTGCC 5992 TCAGCCTCCC AAACAAACAA ACAACCCCAC AGTTTAATAT GTGTTACAAC ACACATGCTG 6052 CAACTTTTAT GAGTATTTTA ATGATATAGA TTATAAAAGG TTGTTTTTAA CTTTTAAATG 6112 CTGGGATTAC AGGCATGAGC CACTGTGCCA GGCCTGAACT GTGTTTTTAA AAATGTCTGA 6172 CCAGCTGTAC ATAGTCTCCT GCAGACTGGC CAAGTCTCAA AGTGGGAACA GGTGTATTAA 6232 GGACTATCCT TTGGTTAAAT TTCCGCAAAT GTTCCTGTGC AAGAATTCTT CTAACTAGAG 6292 TTCTCATTTA TTATATTTAT TTCAG AT AAT GCA CCC CGG ACC ATA TTT ATT 6343 Asp Asn Ala Pro Arg Thr Ile Phe Ile 40 45 ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 6391 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 TCT GTG AAG TGT GAG AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT 6439 Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 ATT TCC TTT AAG GTAAG ACTGAGCCTT ACTTTGTTTT CAATCATGTT AATATAATCA 6496 Ile Ser Phe Lys ATATAATTAG AAATATAACA TTATTTCTAA TGTTAATATA AGTAATGTAA TTAGAAAACT 6556 CAAATATCCT CAGACCAACC TTTTGTCTAG AACAGAAATA ACAAGAAGCA GAGAACCATT 6616 AAAGTGAATA CTTACTAAAA ATTATCAAAC TCTTTACCTA TTGTGATAAT GATGGTTTTT 6676 CTGAGCCTGT CACAGGGGAA GAGGAGATAC AACACTTGTT TTATGACCTG CATCTCCTGA 6736 ACAATCAGTC TTTATACAAA TAATAATGTA GAATACATAT GTGAGTTATA CATTTAAGAA 6796 TAACATGTGA CTTTCCAGAA TGAGTTCTGC TATGAAGAAT GAAGCTAATT ATCCTTCTAT 6856 ATTTCTACAC CTTTGTAAAT TATGATAATA TTTTAATCCC TAGTTGTTTT GTTGCTGATC 6916 CTTAGCCTAA GTCTTAGACA CAAGCTTCAG CTTCCAGTTG ATGTATGTTA TTTTTAATGT 6976 TAATCTAATT GAATAAAAGT TATGAGATCA GCTGTAAAAG TAATGCTATA ATTATCTTCA 7036 AGCCAGGTAT AAAGTATTTC TGGCCTCTAC TTTTTCTCTA TTATTCTCCA TTATTATTCT 7096 CTATTATTTT TCTCTATTTC CTCCATTATT GTTAGATAAA CCACAATTAA CTATAGCTAC 7156 AGACTGAGCC AGTAAGAGTA GCCAGGGATG CTTACAAATT GGCAATGCTT CAGAGGAGAA 7216 TTCCATGTCA TGAAGACTCT TTTTGAGTGG AGATTTGCCA ATAAATATCC GCTTTCATGC 7276 CCACCCAGTC CCCACTGAAA GACAGTTAGG ATATGACCTT AGTGAAGGTA CCAAGGGGCA 7336 ACTTGGTAGG GAGAAAAAAG CCACTCTAAA ATATAATCCA AGTAAGAACA GTGCATATGC 7396 AACAGATACA GCCCCCAGAC AAATCCCTCA GCTATCTCCC TCCAACCAGA GTGCCACCCC 7456 TTCAGGTGAC AATTTGGAGT CCCCATTCTA GACCTGACAG GCAGCTTAGT TATCAAAATA 7516 GCATAAGAGG CCTGGGATGG AAGGGTAGGG TGGAAAGGGT TAAGCATGCT GTTACTGAAC 7576 AACATAATTA GAAGGGAAGG AGATGGCCAA GCTCAAGCTA TGTGGGATAG AGGAAAACTC 7636 AGCTGCAGAG GCAGATTCAG AAACTGGGAT AAGTCCGAAC CTACAGGTGG ATTCTTGTTG 7696 AGGGAGACTG GTGAAAATGT TAAGAAGATG GAAATAATGC TTGGCACTTA GTAGGAACTG 7756 GGCAAATCCA TATTTGGGGG AGCCTGAAGT TTATTCAATT TTGATGGCCC TTTTAAATAA 7816 AAAGAATGTG GCTGGGCGTG GTGGCTCACA CCTGTAATCC CAGCACTTTG GGAGGCCGAG 7876 GGGGGCGGAT CACCTGAAGT CAGGAGTTCA AGACCAGCCT GACCAACATG GAGAAACCCC 7936 ATCTCTACTA AAAATACAAA ATTAGCTGGG CGTGGTGGCA TATGCCTGTA ATCCCAGCTA 7996 CTCGGGAGGC TGAGGCAGGA GAATCTTTTG AACCCGGGAG GCAGAGGTTG CGATGAGCCT 8056 AGATCGTGCC ATTGCACTCC AGCCTGGGCA ACAAGAGCAA AACTCGGTCT CAAAAAAAAA 8116 AAAAAAAAAG TGAAATTAAC CAAAGGCATT AGCTTAATAA TTTAATACTG TTTTTAAGTA 8176 GGGCGGGGGG TGGCTGGAAG AGATCTGTGT AAATGAGGGA ATCTGACATT TAAGCTTCAT 8236 CAGCATCATA GCAAATCTGC TTCTGGAAGG AACTCAATAA ATATTAGTTG GAGGGGGGGA 8296 GAGAGTGAGG GGTGGACTAG GACCAGTTTT AGCCCTTGTC TTTAATCCCT TTTCCTGCCA 8356 CTAATAAGGA TCTTAGCAGT GGTTATAAAA GTGGCCTAGG TTCTAGATAA TAAGATACAA 8416 CAGGCCAGGC ACAGTGGCTC ATGCCTATAA TCCCAGCACT TTGGGAGGGC AAGGCGAGTG 8476 TCTCACTTGA GATCAGGAGT TCAAGACCAG CCTGGCCAGC ATGGCGATAC TCTGTCTCTA 8536 CTAAAAAAAA TACAAAAATT AGCCAGGCAT GGTGGCATGC ACCTGTAATC CCAGCTACTC 8596 GTGAGCCTGA GGCAGAAGAA TCGCTTGAAA CCAGGAGGTG TAGGCTGCAG TGAGCTGAGA 8656 TCGCACCACT GCACTCCAGC CTGGGCGACA GAATGAGACT TTGTCTCAAA AAAAGAAAAA 8716 GATACAACAG GCTACCCTTA TGTGCTCACC TTTCACTGTT GATTACTAGC TATAAAGTCC 8776 TATAAAGTTC TTTGGTCAAG AACCTTGACA ACACTAAGAG GGATTTGCTT TGAGAGGTTA 8836 CTGTCAGAGT CTGTTTCATA TATATACATA TACATGTATA TATGTATCTA TATCCAGGCT 8896 TGGCCAGGGT TCCCTCAGAC TTTCCAGTGC ACTTGGGAGA TGTTAGGTCA ATATCAACTT 8956 TCCCTGGATT CAGATTCAAC CCCTTCTGAT GTAAAAAAAA AAAAAAAAAA GAAAGAAATC 9016 CCTTTCCCCT TGGAGCACTC AAGTTTCACC AGGTGGGGCT TTCCAAGTTG GGGGTTCTCC 9076 AAGGTCATTG GGATTGCTTT CACATCCATT TGCTATGTAC CTTCCCTATG ATGGCTGGGA 9136 GTGGTCAACA TCAAAACTAG GAAAGCTACT GCCCAAGGAT GTCCTTACCT CTATTCTGAA 9196 ATGTGCAATA AGTGTGATTA AAGAGATTGC CTGTTCTACC TATCCACACT CTCGCTTTCA 9256 ACTGTAACTT TCTTTTTTTC TTTTTTTCTT TTTTTCTTTT TTTTTGAAAC GGAGTCTCGC 9316 TCTGTCGCCC AGGCTAGAGT GCAGTGGCAC GATCTCAGCT CACTGCAAGC TCTGCCTCCC 9376 GGGTTCACGC CATTCTCCTG CCTCACCCTC CCAAGCAGCT GGGACTACAG GCGCCTGCCA 9436 CCATGCCCAG CTAATTTTTT GTATTTTTAG TAGAGACGGG GTTTCACCGT GTTAGCCAGG 9496 ATGGTCTCGA TCTCCTGAAC TTGTGATCCG CCCGCCTCAG CCTCCCAAAG TGCTGGGATT 9556 ACAGGCGTGA GCCATCGCAC CCGGCTCAAC TGTAACTTTC TATACTGGTT CATCTTCCCC 9616 TGTAATGTTA CTAGAGCTTT TGAAGTTTTG GCTATGGATT ATTTCTCATT TATACATTAG 9676 ATTTCAGATT AGTTCCAAAT TGATGCCCAC AGCTTAGGGT CTCTTCCTAA ATTGTATATT 9736 GTAGACAGCT GCAGAAGTGG GTGCCAATAG GGGAACTAGT TTATACTTTC ATCAACTTAG 9796 GACCCACACT TGTTGATAAA GAACAAAGGT CAAGAGTTAT GACTACTGAT TCCACAACTG 9856 ATTGAGAAGT TGGAGATAAC CCCGTGACCT CTGCCATCCA GAGTCTTTCA GGCATCTTTG 9916 AAGGATGAAG AAATGCTATT TTAATTTTGG AGGTTTCTCT ATCAGTGCTT AGGATCATGG 9976 GAATCTGTGC TGCCATGAGG CCAAAATTAA GTCCAAAACA TCTACTGGTT CCAGGATTAA 10036 CATGGAAGAA CCTTAGGTGG TGCCCACATG TTCTGATCCA TCCTGCAAAA TAGACATGCT 10096 GCACTAACAG GAAAAGTGCA GGCAGCACTA CCAGTTGGAT AACCTGCAAG ATTATAGTTT 10156 CAAGTAATCT AACCATTTCT CACAAGGCCC TATTCTGTGA CTGAAACATA CAAGAATCTG 10216 CATTTGGCCT TCTAAGGCAG GGCCCAGCCA AGGAGACCAT ATTCAGGACA GAAATTCAAG 10276 ACTACTATGG AACTGGAGTG CTTGGCAGGG AAGACAGAGT CAAGGACTGC CAACTGAGCC 10336 AATACAGCAG GCTTACACAG GAACCCAGGG CCTAGCCCTA CAACAATTAT TGGGTCTATT 10396 CACTGTAAGT TTTAATTTCA GGCTCCACTG AAAGAGTAAG CTAAGATTCC TGGCACTTTC 10456 TGTCTCTCTC ACAGTTGGCT CAGAAATGAG AACTGGTCAG GCCAGGCATG GTGGCTTACA 10516 CCTGGAATCC CAGCACTTTG GGAGGCCGAA GTGGGAGGGT CACTTGAGGC CAGGAGTTCA 10576 GGACCAGCTT AGGCAACAAA GTGAGATACC CCCTGACCCC TTCTCTACAA AAATAAATTT 10636 TAAAAATTAG CCAAATGTGG TGGTGTATAC TTACAGTCCC AGCTACTCAG GAGGCTGAGG 10696 CAGGGGGATT GCTTGAGCCC AGGAATTCAA GGCTGCAGTG AGCTATGATT TCACCACTGC 10756 ACTTCTGGCT GGGCAACAGA GCGAGACCCT GTCTCAAAGC AAAAAGAAAA AGAAACTAGA 10816 ACTAGCCTAA GTTTGTGGGA GGAGGTCATC ATCGTCTTTA GCCGTGAATG GTTATTATAG 10876 AGGACAGAAA TTGACATTAG CCCAAAAAGC TTGTGGTCTT TGCTGGAACT CTACTTAATC 10936 TTGAGCAAAT GTGGACACCA CTCAATGGGA GAGGAGAGAA GTAAGCTGTT TGATGTATAG 10996 GGGAAAACTA GAGGCCTGGA ACTGAATATG CATCCCATGA CAGGGAGAAT AGGAGATTCG 11056 GAGTTAAGAA GGAGAGGAGG TCAGTACTGC TGTTCAGAGA TTTTTTTTAT GTAACTCTTG 11116 AGAAGCAAAA CTACTTTTGT TCTGTTTGGT AATATACTTC AAAACAAACT TCATATATTC 11176 AAATTGTTCA TGTCCTGAAA TAATTAGGTA ATGTTTTTTT CTCTATAG GAA ATG AAT 11233 Glu Met Asn 85 CCT CCT GAT AAC ATC AAG GAT ACA AAA AGT GAC ATC ATA TTC TTT CAG 11281 Pro Pro Asp Asn Ile Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Glu 90 95 100 AGA AGT GTC CCA GGA CAT GAT AAT AAG ATG CAA TTT GAA TCT TCA TCA 11329 Arg Ser Val Pro Gly His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser 105 110 115 TAC GAA GGA TAC TTT CTA GCT TGT GAA AAA GAG AGA GAC CTT TTT AAA 11377 Tyr Glu Gly Tyr Phe Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys 120 125 130 135 CTC ATT TTG AAA AAA GAG GAT GAA TTG GGG GAT AGA TCT ATA ATG TTC 11425 Leu Ile Leu Lys Lys Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe 140 145 150 ACT GTT CAA AAC GAA GAC TAGCTATTAA AATTTCATGC C 11464 Thr Val Gln Asn Glu Asp 155 471 base pairs nucleic acid double linear cDNA to mRNA mouse liver mat peptide 1..471 S 18 AAC TTT GGC CGA CTT CAC TGT ACA ACC GCA GTA ATA CGG AAT ATA AAT 48 Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn 1 5 10 15 GAC CAA GTT CTC TTC GTT GAC AAA AGA CAG CCT GTG TTC GAG GAT ATG 96 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met 20 25 30 ACT GAT ATT GAT CAA AGT GCC AGT GAA CCC CAG ACC AGA CTG ATA ATA 144 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile 35 40 45 TAC ATG TAC AAA GAC AGT GAA GTA AGA GGA CTG GCT GTG ACC CTC TCT 192 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser 50 55 60 GTG AAG GAT AGT AAA ATG TCT ACC CTC TCC TGT AAG AAC AAG ATC ATT 240 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile 65 70 75 80 TCC TTT GAG GAA ATG GAT CCA CCT GAA AAT ATT GAT GAT ATA CAA AGT 288 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser 85 90 95 GAT CTC ATA TTC TTT CAG AAA CGT GTT CCA GGA CAC AAC AAG ATG GAG 336 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu 100 105 110 TTT GAA TCT TCA CTG TAT GAA GGA CAC TTT CTT GCT TGC CAA AAG GAA 384 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu 115 120 125 GAT GAT GCT TTC AAA CTC ATT CTG AAA AAA AAG GAT GAA AAT GGG GAT 432 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp 130 135 140 AAA TCT GTA ATG TTC ACT CTC ACT AAC TTA CAT CAA AGT 471 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser 145 150 155 9 amino acids amino acid linear peptide N-terminal fragment 19 Asn Phe Gly Arg Leu His Cys Thr Thr 1 5 157 amino acids amino acid linear peptide 20 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 21 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 22 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 23 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 24 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ser Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 25 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 26 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 1 5 10 15 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile 65 70 75 80 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 85 90 95 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 100 105 110 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu 115 120 125 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 130 135 140 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 145 150 155 157 amino acids amino acid linear peptide 27 Asn Phe Gly Arg Leu His Ala Thr Thr Ala Val Ile Arg Asn Ile Asn 1 5 10 15 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met 20 25 30 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile 35 40 45 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser 50 55 60 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile 65 70 75 80 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser 85 90 95 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu 100 105 110 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu 115 120 125 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp 130 135 140 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser 145 150 155 157 amino acids amino acid linear peptide 28 Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn 1 5 10 15 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met 20 25 30 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile 35 40 45 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser 50 55 60 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile 65 70 75 80 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser 85 90 95 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu 100 105 110 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Ser Gln Lys Glu 115 120 125 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp 130 135 140 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser 145 150 155

Claims

We claim:

1. An osteoclastgenic inhibitory agent, which comprises an interleukin-18 or its functional equivalent.

2. The inhibitory agent of claim 1, wherein said interleukin-18 includes the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 as partial amino acid sequences.

3. The inhibitory agent of claim 1, wherein said interleukin-18 includes the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5 as partial amino acid sequences.

4. The inhibitory agent of claim 1, wherein said interleukin-18 includes the amino acid sequence of SEQ ID NO: 6.

5. The inhibitory agent of claim 1, wherein said interleukin-18 is human origin.

6. The inhibitory agent of claim 1, wherein said interleukin-18 includes the amino acid sequence of SEQ ID NO: 7.

7. The inhibitory agent of claim 1, which is a therapeutic agent for osteoclast-related diseases.

8. The inhibitory agent of claim 1, which contains a protein, buffer, or saccharide as a stabilizer.

9. The inhibitory agent of claim 1, which is in the form of a liquid, paste, or solid.

10. The inhibitory agent of claim 1, which contains 0.000002-100 w/w % of said interleukin-18.

11. A method for treating and/or preventing osteoclast-related diseases, which comprising administering said inhibitory agent of claim 1 to patients suffering from said diseases at a dose of about 0.5 μg to 100 mg per shot, 2 to 6 fold a day or 2 to 10 fold a week for one day to one year.